Singapore-based Rockeby Biomed has signed a letter of intent (LOI) with Sandoz China, a subsidiary of Shanghai Novartis Trading to market Pepp in China.

The LOI outlines that Sandoz will carry out market research to fine-tune marketing plans and pricing strategy, while Rockeby concurrently will register the product as a health supplement with the Chinese authorities. Sandoz China will be the exclusive marketing and distribution partner for Pepp.

Pepp is an enzyme-based health supplement, which is able to reduce alcohol levels by more than 50 percent within 40 minutes. It also reduces hangover, eliminate bad breath and promote general gastrointestinal health.

Rockeby's Managing Director and CEO, Dr Sze-Wee Tan, said, “We are expediting the global rollout of Pepp, and China, with its huge population and lifestyle, is a primary target.”

According to market research data, the trade value of the health supplement category for hangover relief in China is currently worth $123 million, which is represented by approximately 70 local products.